Post marketing surveillance of captopril (for hypertension): a preliminary report.

Abstract

1 The methodology and interim results of a post marketing surveillance of captopril, the first orally active angiotensin converting enzyme inhibitor are presented. 2 Utilising viewdata technology, details of hypertensive patients were entered directly into a mainframe computer. This allowed day to day monitoring of events; a facility not available with paper‐based methods. 3 The design of the study allowed analysis of results including some details of efficacy, concomitant therapy, any disease symptoms and reasons for withdrawal. These factors could be categorised according to sex and age. 4 This preliminary report is based on the first 13,295 patients entered from July 1983 with follow‐ up until January 1985. The results of the study confirm the safety of captopril in the patients studied.

Post‐marketing surveillance or drug acceptability study? [editorial]

“…This month in the Journal the first of what may be a long line of 'post marketing surveillance' studies using computer technology appears (Chalmers et al, 1987). The study by Dr Chalmers and colleagues deals with the assessment of captopril for the treatment of hypertension in general practice.…”

Safety and Efficacy of Imidapril in the Treatment of Essential Hypertension

“…For example, angioedema, dizziness, headache, general fatigue, hypotension, gastrointestinal (GI) symptoms, rash, cough, taste disorder and arrhythmia, etc (Supplementary Table 1). [29][30][31][32][33][34][35][36][37][38][39] For imidapril there are some reports on its safety. Dews I and Vandenburg M reported that 46% of patients in the imidapril group and 53% of patients in hydrochlorothiazide group showed at least one adverse event in the multicenter, randomized, double-blind study compared oral administration of once-daily imidapril 5-20 mg with hydrochlorothiazide 12.5-50 mg in elderly patients for 24 weeks.…”

Untitled

“…ACE inhibitors have been found to be effective and/or are indicated in the control of hypertension [1], in the progression of renal dysfunction in patients with type 1 diabetes mellitus and proteinuria [2], in reducing morbidity and mortality post-myocardial infarction [3], and in patients with heart failure due to systolic left ventricular dysfunction [4]. Their use, however, has been limited by side effects such as angioedema, cough, rst-dose hypotension, renal dysfunction, rash, and taste disturbances [5,6]. These side effects are in part related to ACE inhibitor-induced prevention of bradykinin degradation and/or to speci~c properties of individual ACE inhibitors [6].…”

“…Their use, however, has been limited by side effects such as angioedema, cough, rst-dose hypotension, renal dysfunction, rash, and taste disturbances [5,6]. These side effects are in part related to ACE inhibitor-induced prevention of bradykinin degradation and/or to speci~c properties of individual ACE inhibitors [6]. Perceptions as to a relatively high incidence of side effects, especially in the elderly, women, and Asians, have led in part to an underuse of these agents, even where the evidence for their bene~t-as in heart failure due to systolic left ventricular dysfunction, where evidence is based upon prospective, double-blind, randomized trials in many thousands of patients-is overwhelming [7].…”